AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05722340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy
Description: Uses a traditional deep anaesthesia and one-lung ventilation
Study NCT06567366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
Study NCT06567366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant).
Study NCT06567366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study NCT06567080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR201
Description: JWCAR201 is a autologous CAR-T targeting CD19/CD20
Study NCT06146504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CanXida Remove (Formula RMV)
Description: Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
Study NCT06146504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
Study NCT06565598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy
Description: Free through the single layer of the posterior abdominal cavity
Study NCT06536725 — intervention group
Intervention type: OTHER
Intervention: Building Organoid-on-chips models
Description: This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
Study NCT06542796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with targeted therapy
Description: Immunotherapy combined with targeted therapy
Study NCT06542796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment plan
Description: Standard treatment plan
Study NCT06072131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat Injection
Description: Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
Study NCT06072131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate Injection
Description: Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
Study NCT06072131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP is the comparator arm
Study NCT06072131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COP
Description: COP is given in combination with Pralatrexate
Study NCT06043219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17.
Study NCT06043219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17.
Study NCT06043219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Teaching
Description: Traditional anatomical teaching via a powerpoint slide deck
Study NCT06043219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Teaching
Description: Traditional anatomical teaching via a powerpoint slide deck
Study NCT04631406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural Stem Cells
Description: NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
Study NCT04879992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04879992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04879992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05339256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine SL
Description: Up to 24 mg per day
Study NCT05339256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine SL
Description: Up to 24 mg per day
Study NCT05339256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
Study NCT04879992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT04879992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin rifabutin
Description: Antibiotics for H. pylori eradication
Study NCT05339256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person treatment as usual
Description: in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
Study NCT05652036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradetrusor Botox Injections
Description: 100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
Study NCT05830123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study NCT04886232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VP1 Lido US
Description: Hyaluronic acid dermal filler containing lidocaine
Study NCT04886232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic acid dermal filler containing lidocaine
Study NCT04960774 — intervention group
Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention
Study NCT06567522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%
Description: Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
Study NCT04807634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Lipid Emulsion (Intralipid 20%)
Description: Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
Study NCT05089396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary protraction
Description: A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
Study NCT05089396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maxillary protraction
Description: A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
Study NCT05684887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital based contact tracing
Description: * Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module.
Study NCT06505785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The creative drama group
Description: 10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development.
Study NCT04911127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg Cannabidiol by capsules twice daily
Description: 200mg twice daily via 50mg capsules
Study NCT04911127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg Cannabidiol by capsules twice daily
Description: 400mg twice daily via 50mg capsules
Study NCT06263777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurses training program on early detection of disability
Description: It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
Study NCT04911127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: MCT oil capsules as placebo for CBD
Study NCT05243602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to B/F/TAF
Description: This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
Study NCT05243602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue current regimen
Description: Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
Study NCT06147440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Participants receive diets following different dietary patterns for 1 week.
Study NCT05315986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffr'Inside; 30mg
Description: Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
Study NCT05315986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sleep Education
Description: Psycho-education based multi-component sleep intervention
Study NCT05315986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo food supplement
Description: Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
Study NCT05315986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo food supplement
Description: Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
Study NCT04640909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood samples withdrawal
Description: Peripheral blood samples evaluation
Study NCT06540482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reliability test
Description: The test was administered two days apart to evaluate the reliability of the retest test.
Study NCT04629300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care Mobile Application
Description: Tablet computer with application providing modules on skills for managing symptoms and coping.
Study NCT04629300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard oncology care with monitoring of supportive care services usage
Study NCT04629300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard oncology care with monitoring of supportive care services usage
Study NCT05567588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: Pembrolizumab
Description: 200mg(body weight >75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
Study NCT06114017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Abstention
Description: People will stop or reduce their social media use for one week.
Study NCT05309031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion
Description: Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
Study NCT06543511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Blood Test
Description: Germline genetic testing using skin fibroblasts
Study NCT04989231 — intervention group
Intervention type: BIOLOGICAL
Intervention: Investigational sIPV
Description: Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
Study NCT04989231 — intervention group
Intervention type: BIOLOGICAL
Intervention: Control IPV
Description: Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
Study NCT05092451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study NCT05092451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.70/IL15-transduced CB-NK cells
Description: Given by IV
Study NCT05092451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV
Study NCT04395456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMY-101
Description: C3 complement inhibitor
Study NCT04395456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WFI 5% glucose
Description: Placebo
Study NCT06451757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonlicromanol
Description: Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks
Study NCT06451757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of 100 mg placebo twice daily during 52 weeks
Study NCT06497907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polymeric formula
Description: Patients with growth faltering received nutritional rehabilitation with polymeric formula and were reassessed after 12 weeks by anthropometric measurements
Study NCT06497907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: peptide based formula
Description: patients who were defined as non responders and underwent upper gastrointestinal endoscopy and diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula
Study NCT05651594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue collection
Study NCT05651594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05651594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT05651594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05651594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT05651594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05651594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05651594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO
Study NCT05651594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Perceived Stress Scale
Study NCT06181773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPO Feeding Program
Description: The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
Study NCT05860608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Us2.ai (AI-enabled report) handheld echocardiogram
Description: NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
Study NCT05860608 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Us2.ai (AI-enabled report) handheld echocardiogram
Description: NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
Study NCT04815356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22CART cell infusion
Description: The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 post-CD22CART infusion.
Study NCT05785754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCSZ11
Description: A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Study NCT06116773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds.